News

Aduhelm, a revolutionary approval; mapping the road to the clinic

The 'what' that matters - questions worth asking

Telehealth: Tackling Evolving Competitive Landscapes in Response to a Megatrend

Is Pre-Hospital Administration the Future for Antiplatelet Therapies?

15 Years of Biosimilars: Lessons Learnt and What’s Next

Have ‘smart’ devices arrived in healthcare? The emergence of digitally connected combination products

China Market Access: Opportunity or Obstacle?

Why war games are not the answer to understanding markets - Part Two

The rise of real-world evidence in the pharmaceutical industry

A view through the weeds: Where do we stand on medical cannabis

Why war games are not the answer to understanding markets - Part One

Review: Competitive Intelligence in Pharma and Life Science Event

A Hidden Gen: The Billion Dollar US Generic Injectables Market

Synthetic control arms – use of RWE in clinical trials

Virtual Conferences: A Year in Review and Future Direction

The war on vaccines in a post-COVID world

Part II-Should Your Strategy be a Destination or a Journey

Why 2021 Will Be A Fiercely Competitive Year In The Human Growth Hormone (hGH) Market

Part I-Should Your Strategy Be A Destination Or A Journey?

Unlocking the Opportunity in Axial Spondyloarthritis - Treating the Visible and the Invisible

Could targeting lysosomal dysfunction be the key to treating Parkinson’s disease?

From cholesterol to COVID-19: RNA therapeutics as an emerging treatment approach

Could CDK4/6 inhibitors be established in early-stage HR+ breast cancer?

Cancer Cachexia – no time to waste

The US Biosimilar Landscape is Heating Up

The Gene Therapy Revolution Has Arrived. But What’s Next?

Managing cancer patients during the COVID-19 pandemic

COVID-19: Dissecting the therapeutic and vaccine landscape: Volume II

Hidden opportunity in a time of crisis: Rheumatology’s assets at the COVID-19 frontline

COVID-19: Dissecting the therapeutic and vaccine landscape: Volume I

The Show Must Go On: Virtual conferences and primary insights

Nexletol and Nexlizet approvals: a heart-warming price in a space defeated with pricing battles?

Tumor Mutational Burden: end of the road or an uphill battle for acceptance as an immuno-oncology biomarker?

Will PSMA-targeting diagnostics and therapeutics revolutionize Prostate Cancer care?

CTAD Impressions: Is there finally going to be a disease modifying therapy approved for Alzheimer’s?

Rapid Approvals & Innovative Approaches, But Which Sickle Cell Therapies Will Offer Real Benefits?

Key Insights from ESMO 2019

Top tips for managing a drug franchise in a competitive therapy area

Findacure Rare Disease Showcase

Bio Asia Taiwan 2019 Highlights